Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02040792 · ClinicalTrials.gov registry record · Phase 2

A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 study, sponsored by Mylan.

Completed
Registry status
Phase 2
Development phase
355
Enrollment target

NCT02040792 is a Phase 2 study that has completed, run by Mylan. The registered enrollment target is 355 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02040792, a Phase 2 study, has completed, sponsored by Mylan.

COMPLETED
Registry status
Phase 2
Development phase
355 participants
Enrollment target

Study Summary

This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.

Interventions

  • DRUG Placebo
  • DRUG TD-4208

Trial Details

FieldValue
Enrollment Target 355 participants
Start Date 2014-05
Est. Completion 2014-08
Phase Phase 2

Sponsor

Mylan

22 total trials

What the Registry Record Tells You About NCT02040792

The ClinicalTrials.gov registry entry for NCT02040792 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02040792 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02040792 about?

NCT02040792 is a clinical study titled "A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)". This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.

What is the current status of trial NCT02040792?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 355 participants. The study started on 2014-05. Estimated completion is 2014-08.

What interventions are being tested in trial NCT02040792?

The interventions under investigation include: Placebo (DRUG), TD-4208 (DRUG).

Who is sponsoring clinical trial NCT02040792?

This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.